☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE Guidance - June 2021

The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of June 2021. This month are seven guidelines and one technology appraisal that impact upon primary care.

The COVID-19 rapid guideline: managing COVID-19 guideline has been updated. It covers the management of COVID-19 for children, young people and adults in all care settings. The update references publication via a global evidence platform.

The Atrial fibrillation: diagnosis and management guideline has been updated. It covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding. The update recommends using the ORBIT score to assess bleeding risk.

The Autism spectrum disorder in under 19s: support and management guideline has been updated. It covers the different ways that health and social care professionals can provide support, treatment and help for children and young people with autism, and their families and carers, from the early years through to their transition into young adult life. This updates adds new recommendations on interventions for feeding problems, including restricted diets.

The Autism spectrum disorder in adults: diagnosis and management guideline has been updated. It covers diagnosing and managing suspected or confirmed autism spectrum disorder in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism. The update clarifies that a person who scores 6 or above on the AQ-10 should be offered a comprehensive assessment.

The Shared decision making guideline has been published. It covers how to make shared decision making part of everyday care in all healthcare settings. It promotes ways for healthcare professionals and people using services to work together to make decisions about treatment and care. It includes recommendations on training, communicating risks, benefits and consequences, using decision aids, and how to embed shared decision making in organisational culture and practices.

The Patient experience in adult NHS services guideline has been updated. It covers the components of a good patient experience. It aims to make sure that all adults using NHS services have the best possible experience of care. The update replaces several recommendations on share decision making and refers to the newly published guideline mentioned above.

The Acne vulgaris: management guideline has been published. It covers the management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.

The Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis technology appraisal has been published. This treatment is recommended as an option for inducing remission of eosinophilic oesophagitis in adults. It is noted that since the appraisal process began the product license has been extended to include maintenance treatment but as no evidence was submitted for this newly licensed indication no recommendation is made at this time for maintenance.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - June 2021' on Email Share 'NICE Guidance - June 2021' on Delicious Share 'NICE Guidance - June 2021' on Digg Share 'NICE Guidance - June 2021' on Facebook Share 'NICE Guidance - June 2021' on reddit Share 'NICE Guidance - June 2021' on Twitter

Drug Safety Update - June 2021

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for June 2021 (PDF).

This month readers are advised of reports of interstitial lung disease and pneumonitis associated with use of CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼). Patients taking these medicines should be made aware of the need to seek advice right away if they develop new or worsening respiratory symptoms at clinic reviews. Patients on these medicines who present in primary care with respiratory symptoms should be managed cautiously and should be advised to make contact with their specialist.

Readers are also advised of the risk of severe cutaneous adverse reactions (SCARs) including SJS and TEN associated with use of atezolizumab▼ (Tecentriq®) and other immune-stimulatory anti-cancer drugs. Patients on these drugs should be advised by their specialist to be vigilant for the signs of severe skin reactions and to seek urgent medical advice if they occur. In such cases continued treatment should be withheld, and patients referred to a specialist for diagnosis and treatment.

This issue also contains an update on COVID-19 vaccines and medicines that includes information on a newly licensed vaccine from Janssen and licence extension to younger age groups for the Pfizer/BioNTech vaccine.

Finally in this issue is a summary of letters to healthcare professionals sent in May that were regarding product recalls.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - June 2021' on Email Share 'Drug Safety Update - June 2021' on Delicious Share 'Drug Safety Update - June 2021' on Digg Share 'Drug Safety Update - June 2021' on Facebook Share 'Drug Safety Update - June 2021' on reddit Share 'Drug Safety Update - June 2021' on Twitter

SMC Update - June 2021

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

5-aminolevulinic acid (Alacare®) has been accepted for single use treatment of mild actinic keratoses lesions with a maximum diameter of 1.8 cm on the face and scalp (hairless areas). It is noted that another licensed formulation of 5-aminolevulinic acid is available and there may be an associated small net budget impact with the use of this product.

Vigabatrin (Kigabeq®) has been accepted for restricted use in infants and children from 1 month to less than 7 years of age for:

  • treatment in monotherapy of infantile spasms (West's syndrome)
  • treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated

The restriction limits use to patients in whom other formulations of vigabatrin are not suitable.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - June 2021' on Email Share 'SMC Update - June 2021' on Delicious Share 'SMC Update - June 2021' on Digg Share 'SMC Update - June 2021' on Facebook Share 'SMC Update - June 2021' on reddit Share 'SMC Update - June 2021' on Twitter

CKS Updates - May 2021

During May 2021 Clinical Knowledge Summaries were published or updated in the following areas.

All topics have been reviewed and updated in keeping with current guidance with minor layout changes. No major changes have been made within these topics.

Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.

Share 'CKS Updates - May 2021' on Email Share 'CKS Updates - May 2021' on Delicious Share 'CKS Updates - May 2021' on Digg Share 'CKS Updates - May 2021' on Facebook Share 'CKS Updates - May 2021' on reddit Share 'CKS Updates - May 2021' on Twitter

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.

vipers